Conference on Endothelin: Physiology, Pathophysiology and Therapeutics

 描述（由申请人提供）：本提案的目的是寻求对定于2015年9月2日至5日在格鲁吉亚萨凡纳举行的题为“第14届内皮素国际会议：生理学、病理生理学和治疗学”的APS会议的支持。会议每隔一年举行一次，在欧洲、亚洲和北美轮流举行。它已发展成为科学家会面和讨论基础内皮素（ET）研究的最新进展以及阻断ET系统的临床应用和将ET用作疾病生物标志物的首要论坛。会议计划结合了来自权威机构的演讲和来自ET领域年轻研究人员的演讲。与过去一样，会议将重点关注健康和疾病中的心血管系统，重点是将基础研究转化为高血压、心肌梗死、动脉粥样硬化、肾衰竭、糖尿病和肺动脉高压的主要临床问题。海报会议的充足时间将允许深入讨论，特别精选的海报会议将突出学生，研究员和年轻科学家正在进行的研究。会议的目标是：1）召集一个国际公认的跨学科研究小组，讨论当前的基础和临床研究结果， ET地区。会议的目的是讨论正在进行的研究和与该专题有关的问题，并概述未来工作的方向。2)通过旅行奖励计划，促进青年科学家广泛参加这次会议，重点是妇女和代表性不足的少数民族。3)翻译从事ET生物学基础和临床研究的新研究人员和学生的工作，其总体目标是将这些发现与心血管系统，肺和肾脏疾病，糖尿病，癌症和疼痛的主要临床问题联系起来。美国物理学会同意主办这次会议，因为这个主题是广泛的综合性和跨学科的性质，很像生理学学科。ET在包括肺、肾、心脏和脑在内的大多数器官系统的血管疾病中起着至关重要的作用。此外，来自非血管来源的ET有助于控制水和电解质的运输、交感神经活动的调节以及胃肠系统的发育。这些方面为APS提供了一个独特的机制，使其在常规APS成员之外有广泛的接触和招募科学界的机会。1988年ET的发现导致了关于ET肽的生理和病理作用的信息的虚拟爆炸，已经产生了超过25，000篇论文。在高质量基础科学的推动下，继续有许多采用ET拮抗剂的I、II和III期临床试验。自从肺动脉高压试验成功以来，ET拮抗剂和ET转换酶抑制剂在涉及心血管、神经、呼吸、胃肠道、泌尿和生殖系统的疾病中的应用越来越受到关注。ET系统的临床相关性确保了ET会议在广泛的制药公司的大力支持下具有转化性。

 DESCRIPTION (provided by applicant): The purpose of this proposal is to seek support for the APS Conference entitled "14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics," scheduled for September 2-5, 2015 in Savannah, Georgia. The meeting is held every other year and rotates between Europe, Asia and North America. It has evolved into the premier forum for scientists to meet and discuss recent developments in basic endothelin (ET) research as well as clinical applications of blocking the ET system and the use of ET as a biomarker for disease. The conference program combines presentations from leading authorities with presentations from young investigators in the ET field. As in the past, the meeting will have a strong focus on the cardiovascular system in health and disease, with an emphasis on translating basic research to major clinical issues in hypertension, myocardial infarction, atherosclerosis, renal failure, diabetes, and pulmonary hypertension. Ample time for poster sessions will allow for in-depth discussions, and special featured poster sessions will highlight ongoing research of students, fellows, and young scientists. The objectives of the conference are: 1) To convene an internationally recognized, interdisciplinary group of investigators to discuss current basic and clinical research findings in the area of ET. The aim of the meeting is to both discuss the ongoing research and issues related to the topic, as well as outline the direction for future work. 2) To promote the wide-spread participation of young scientists in this Conference, with an emphasis on women and underrepresented minorities, through a travel award program. 3) To translate work by new investigators and students pursuing basic and clinical research in ET biology with the overall objective of relating these findings to major clinical issues in the cardiovascular system, pulmonary and renal disease, diabetes, cancer and pain. The APS has agreed to host this meeting because the topic is broadly integrative and interdisciplinary in nature, much like the discipline of physiology. ET plays a critically important role in vascular disorders of most organ systems including the lung, kidneys, heart, and brain. In addition, ET from non-vascular origins contributes to control water and electrolyte transport, modulation of sympathetic nerve activity, and development of the gastrointestinal system. These aspects provide a unique mechanism for APS to have broad exposure and recruitment opportunities to scientific communities beyond the regular APS membership. The discovery of ET in 1988 led to a virtual explosion of information on the physiological and pathological role of ET peptides that has spawned more than 25,000 papers. Driven by high quality basic science, there continues to be a number of Phase I, II and III clinical trials employing ET antagonists. Since the successful trials on pulmonary hypertension, a growing interest in the use of ET antagonists and ET converting enzyme inhibitors in diseases involving the cardiovascular, nervous, respiratory, gastrointestinal, urinar and reproductive systems have been registered. The clinical relevance of the ET system has ensured that the ET conferences are translational in nature with tremendous support from a wide range of pharmaceutical companies.